The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.
The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.
Patent No.:
Date of Patent:
Mar. 25, 2025
Filed:
Jul. 11, 2023
Applicant:
Inxmed (Nanjing) Co., Ltd., Nanjing, CN;
Inventors:
Assignee:
INXMED (NANJING) CO., LTD., Nanjing, CN;
Attorney:
Primary Examiner:
Assistant Examiner:
Int. Cl.
CPC ...
A61K 31/506 (2006.01); A61K 31/4439 (2006.01); A61K 31/5377 (2006.01); A61K 45/06 (2006.01); A61P 1/00 (2006.01); A61P 17/00 (2006.01); A61P 19/04 (2006.01); A61P 35/00 (2006.01);
U.S. Cl.
CPC ...
A61K 31/506 (2013.01); A61K 31/4439 (2013.01); A61K 31/5377 (2013.01); A61K 45/06 (2013.01); A61P 1/00 (2018.01); A61P 17/00 (2018.01); A61P 19/04 (2018.01); A61P 35/00 (2018.01);
Abstract
A use of a FAK inhibitor in the preparation of a drug for preventing and/or treating tumors having an NRAS mutation. A method for treating tumors that have experienced an NRAS mutation, which comprises administering an effective dose of a FAK inhibitor to an individual. A FAK inhibitor for treating tumors having an NRAS mutation. The FAK inhibitor is B1853520, defactinib, GSK2256098, PF-00562271, VS-4718 or a pharmaceutically acceptable salt thereof.